FUJIKURA
23.10.2020 10:02:07 CEST | Business Wire | Press release
Fujikura Ltd. (TOKYO:5803) (President & CEO: Masahiko Ito) today announced the introduction of industry’s most advanced and highly integrated Phased Array Antenna Module (PAAM) for 5G mmWave operating in 3GPP bands n257 (28 GHz), n258 (26 GHz) and n261 (27 GHz). The Fujikura PAAM is the industry’s highest performance PAAM targeting indoor and outdoor applications such as 5G mmWave Fixed Wireless Access (FWA), 5G mmWave Mobile Wireless Access (MWA), 5G mmWave wireless backhaul, and other emerging applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201023005099/en/
Key Differentiating Features of the Fujikura PAAM
The Fujikura PAAM is a high performance phased array antenna module with a novel integrated antenna, and supports concurrent dual polarized beams in both transmission and reception (Fig.1). The PAAM integrates best-in-class mmWave-ICs developed in-house using an industry leading SiGe BiCMOS process. The PAAM features extremely low noise figure (NF) characteristics and enables a large link margin for expanded coverage. Tunable true-time-delay-type phase shifters support precise and independent phase and amplitude control over a wide frequency range. The unique phase shifter not only enables simple beam-steering control which allows accurate beam steering with fine resolution, but also allows calibration-free operation making PAAM installation much easier. The phase shifter also maintains the transmitted or received signals undistorted by providing invariant group delay and unchanged beam direction in a wide frequency range. In addition, Fujikura PAAM provides superior digital reconfigurability allowing (1) flexible choices in the trade-off space between NF and linearity --- this enables a wide range of coverage applications simply through digital reconfiguration of the PAAM, and (2) on-chip support for 1000s of beam configurations. These are exactly the features highly desired by 5G wireless equipment manufacturers.
5G mmWave Market Growth
Currently, 5G deployments are accelerating around the world and mmWave bands are expected to play a significant role in enhancing the network capabilities. According to the Global mobile Suppliers Association (GSA), by the end of August, 2020, 397 operators in 129 countries and territories had announced investments in 5G. The deployment of 5G mmWave has started primarily in the US market for FWA and MWA, and we are now in the early stages. Markets are expecting substantial increase in 5G mmWave use cases including both outdoor and indoor deployments around the world. Fujikura will contribute to this market growth and benefit from it by providing 5G mmWave infrastructure customers with best-in-class PAAM products.
“Fujikura is announcing its first 5G mmWave RF-IC products for mobile infrastructure. Fujikura n257/n258/n261 PAAM products leverage field proven 5G mmWave IC1 and antenna in package2 technologies developed at IBM Research and enhanced by a Fujikura-led Joint Development Program3,4 . Leveraging our expertise in antenna design and substrate technologies as well as our long history and expertise in delivering differentiating products to the telecom industry, we are excited to introduce our new PAAM product family,” said Kenji Nishide, Fujikura R&D Managing Executive Officer. “Fujikura’s PAAM sets new benchmarks in terms of performance and low power consumption with the highest level of integration for 5G mmWave RF-ICs, which will contribute to growth and expansion of 5G mmWave networks and services.”
Product Introduction Schedule
Fujikura will provide samples for early access customers by the end of 1Q 2021 with volume production in 2H 2021.
For More Information
Please visit our website (https://mmwavetech.fujikura.jp/#area-28ghz-module
) and contact us.
About Fujikura
Fujikura Ltd. is a Tokyo-based company that has been providing wires and cables—“Tsunagu,” or connecting, technologies— to build social infrastructure since its foundation in 1885. With this expertise cultivated over 130 years, we commit to contribute to building social infrastructure by developing products for optical fibers, broadband wireless transmission, superconducting wires, electric vehicles, and other advanced technologies. Fujikura Group has approximately 57,000 employees in more than 30 countries, and posted sales revenue of US$6,178.7 million in Fiscal 2019. Find out more at www.fujikura.co.jp/eng
.
Reference
[1] https://www.ibm.com/blogs/research/2018/02/isscc-lewis-winner-award/
[2] https://www.ibm.com/blogs/research/2017/06/using-air-cavity-boost-performance-5g-antenna-module/
[3] https://www.fujikura.co.jp/eng/newsrelease/products/2058964_11777.html
[4] https://mmwavetech.fujikura.jp/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201023005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom